Abstract
In the original article, there was a mistake in Figure 3 as published. Specifically, the filamentation microscopic figure of C. albicans 0304103 treated with Ganetespib (32 μg/mL) was incorrectly used. This corrigendum provides the corrected visual evidence, reinforcing the study's conclusions regarding the efficacy of Ganetespib in disrupting fungal virulence factors. The authors state that this correction does not alter the scientific conclusions of the article.
Introduction
Candida albicans remains a formidable human pathogen, particularly due to the emergence of azole-resistant strains. These strains utilize complex defense mechanisms, including the formation of protective, multicellular biofilms and the transition from a yeast-like state into invasive filamentous hyphae. Heat Shock Protein 90 (Hsp90) is a critical molecular chaperone that regulates the stress responses and morphological transitions necessary for fungal survival and virulence. This research investigates whether inhibiting Hsp90 with Ganetespib can "re-sensitize" resistant fungi to standard treatments like fluconazole (FLC).
Methods
The researchers utilized clinical isolate 0304103, an azole-resistant strain of C. albicans. The study employed three primary techniques to evaluate efficacy:
- Biofilm Formation Assays: Measuring the percentage of biofilm produced under varying concentrations of Ganetespib and FLC.
- Microscopic Observation: Visually confirming the inhibition of the yeast-to-hyphae transition (filamentation).
- RT-qPCR Analysis: Quantifying the expression levels of eight key genes (ALS1, ALS3, HWP1, EAP1, BCR1, ACE2, RLM1, ZAP1) known to regulate biofilm structure and filamentation.
Results
Synergistic Inhibition of Biofilm Formation
Ganetespib demonstrated a significant, dose-dependent ability to inhibit biofilm formation when combined with fluconazole. While FLC alone showed limited efficacy against the resistant strain, the addition of Ganetespib markedly reduced the multicellular matrix. As shown in the corrected data, increasing concentrations of Ganetespib in the presence of FLC led to a progressive decline in biofilm formation, reaching maximum inhibition at 64 µg/mL.
Disruption of Filamentation and Genetic Reprogramming
Beyond physical biofilm structure, Ganetespib effectively blocked filamentation, keeping the cells in a less invasive, yeast-like state. This phenotypic shift is driven by the downregulation of master regulators. RT-qPCR analysis revealed significant downregulation of HWP1 (a major hyphal wall protein) and BCR1 (a key biofilm regulator), effectively stripping the fungus of its virulence tools. Interestingly, EAP1 showed an increase in expression, suggesting a complex compensatory response to Hsp90 inhibition.
Discussion
The findings underscore the role of Hsp90 as a master regulator of fungal resistance and virulence. By inhibiting Hsp90 with Ganetespib, the researchers were able to bypass standard resistance mechanisms and restore the potency of fluconazole. The downregulation of critical cell wall proteins and transcription factors confirms that Ganetespib acts by fundamentally reprogramming the fungus's ability to adapt to drug stress. While these in vitro results are promising, further in vivo studies are required to evaluate the clinical potential of Ganetespib as an antifungal adjuvant in human patients.
Summary updated